The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success
The Milbank Quarterly · 2024-03 · 102 (1) · 83-96
DOI: 10.1111/1468-0009.12680 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Milbank Quarterly, online erschienen am 12.12.2023. Verfasst von Peter Saltonstall und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Organization for Rare Disorders. Hauptthemen laut MEDLINE: Orphan Drug Production, Drug Approval. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Policy Points The Orphan Drug Act (ODA) was the result of patient advocacy and by many measures has been strikingly successful. However, approximately 95% of the more than 7,000 known rare diseases still have no US Food and Drug Administration–approved treatment. The ODA's success led to sustained criticism of high drug prices, often for products that have orphan drug indications. Critics misconstrue the ODA's intent and propose reducing its incentives instead of pursuing policies focused on addressing broader prescription drug price challenges that exist in both the orphan and nonorphan drug market. Patients and their families will continue to defend the purpose and integrity of the ODA and to drive investments into rare disease research and clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Organization for Rare Disorders.
- Kendall Square Policy Strategies LLC.
Zitieren
APA
Saltonstall, P., Ross, H., & Kim, P. T. (2024). The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success. The Milbank Quarterly, 102(1), 83-96. https://doi.org/10.1111/1468-0009.12680
Vancouver
Saltonstall P, Ross H, Kim PT. The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success. The Milbank Quarterly. 2024;102(1):83-96. doi:10.1111/1468-0009.12680
BibTeX
@article{Saltonstall2024,
author = {Saltonstall, Peter and Ross, Heidi and Kim, Paul T},
title = {The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success},
journal = {The Milbank Quarterly},
year = {2024},
volume = {102},
number = {1},
pages = {83--96},
doi = {10.1111/1468-0009.12680}
}
EUVIMED